Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) [Phase 1]

View source ↗

Summary

The document reports the completed Phase 1 study evaluating escalating doses of the investigational drug forimtamig in relapsed or refractory multiple myeloma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Forimtamig

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED